ストックスクリーナーアプリを入手
26.36
3.86%
0.98
アフターアワーズ：
25.29
-1.07
-4.06%
前日終値:
$25.38
開ける：
$25.58
24時間の取引高:
1.28M
Relative Volume:
1.19
時価総額：
$2.18B
収益：
$352.57M
当期純損益:
$-143.01M
株価収益率:
-14.56
EPS:
-1.81
ネットキャッシュフロー:
$-153.40M
1週間 パフォーマンス:
+4.31%
1か月 パフォーマンス:
-1.31%
6か月 パフォーマンス:
+14.21%
1年 パフォーマンス:
+1.11%
1日の値動き範囲:
$24.76
$27.00
1週間の範囲:
$24.18
$27.00
52週間の値動き範囲:
$20.84
$49.50
Beam Therapeutics Inc Stock (BEAM) Company Profile
名前
Beam Therapeutics Inc
セクター
電話
857-327-8775
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
26.36 | 2.18B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
402.49 | 103.65B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.26 | 78.71B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
645.37 | 38.59B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.15 | 30.07B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.21 | 28.82B | 3.30B | -501.07M | 1.03B | -2.1146 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-08 | ダウングレード | Jefferies | Buy → Hold |
| 2023-10-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 開始されました | Citigroup | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-01-05 | 開始されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-09-24 | 再開されました | Stifel | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Redburn | Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 開始されました | Wells Fargo | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-08-05 | 開始されました | William Blair | Outperform |
| 2020-03-02 | 開始されました | Barclays | Overweight |
| 2020-03-02 | 開始されました | JP Morgan | Overweight |
| 2020-03-02 | 開始されました | Jefferies | Buy |
| 2020-03-02 | 開始されました | Wedbush | Outperform |
すべてを表示
Beam Therapeutics Inc (BEAM) 最新ニュース
Beam Therapeutics Inc. (NASDAQ:BEAM) Insider Sells $30,627.88 in Stock - MarketBeat
Beam Therapeutics chief legal officer sells $30,627 in stock By Investing.com - Investing.com South Africa
Beam Therapeutics chief legal officer sells $30,627 in stock - Investing.com
(BEAM) Technical Pivots with Risk Controls - Stock Traders Daily
Top 5 CRISPR Companies To Invest In (January 2025) - Securities.io
Why Is Beam Therapeutics Inc. (BEAM) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Beam Therapeutics Breaks Below 200-Day Moving AverageNotable for BEAM - Nasdaq
Top 11 CRISPR Stocks to Invest In - Insider Monkey
Beam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Beam Therapeutics (NASDAQ:BEAM) Trading Down 2.6%Time to Sell? - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Geode Capital Management LLC Has $44.30 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
(BEAM) Long Term Investment Analysis - Stock Traders Daily
5 Biotech Breakthrough Stocks to Watch in 2025 - Yahoo Finance
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation - Simply Wall St
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
Beam Therapeutics (BEAM) Stock Dips Amid Biotech Sector Decline - GuruFocus.com
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Beam Therapeutics CEO to Present at J.P. Morgan Healthcare Conference: Precision Gene Editing Spotlight - StockTitan
State Street Corp Purchases 437,402 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Decline in Short Interest - MarketBeat
Beam Therapeutics' SWOT analysis: base editing pioneer faces competitive gene therapy market - Investing.com
Beam Therapeutics' SWOT analysis: base editing pioneer faces competitive gene therapy market By Investing.com - Investing.com South Africa
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains - AOL
Brokers Issue Forecasts for BEAM FY2024 Earnings - MarketBeat
Beam Therapeutics announces new data from BEACON Phase 1/2 trial of BEAM-101 - MSN
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up - MSN
Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers - MSN
Beam Therapeutics (NASDAQ:BEAM) Rating Increased to Hold at Cantor Fitzgerald - MarketBeat
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
Beam Therapeutics shares hold Outperform amid clinical data By Investing.com - Investing.com Canada
Beam Therapeutics shares hold Outperform amid clinical data - Investing.com
Beam Therapeutics Advances BEAM-101 Therapy for Sickle Cell - TipRanks
ASH: Beam’s Base Editor Efficacy In Sickle Cell Disease Holds Up - News & Insights
Beam Therapeutics Achieves Breakthrough in Sickle Cell Treatment with Promising ESCAPE Platform Data - StockTitan
Beam Therapeutics Presents New Non-human Primate (NHP) Data - GlobeNewswire
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for - The Bakersfield Californian
Charles Schwab Investment Management Inc. Boosts Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting - The Manila Times
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 8.6%Here's Why - MarketBeat
BEAMBeam Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire
Beam Therapeutics Reports Breakthrough Clinical Data for Sickle Cell Gene Therapy BEAM-101 - StockTitan
20,800 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Acquired by Polar Asset Management Partners Inc. - MarketBeat
Beam Therapeutics Inc. Appoints Sravan K. Emany as Chief Financial Officer, Effective December 19, 2024 - Marketscreener.com
Beam Therapeutics Names Sravan K. Emany as CFO - TipRanks
Beam Therapeutics names Sravan K. Emany as new CFO - Investing.com
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - The Manila Times
Beam Therapeutics Names Former Ironwood CFO & Banking Veteran Sravan Emany as New Finance Chief - StockTitan
Beam Therapeutics Inc (BEAM) 財務データ
収益
当期純利益
現金流量
EPS
3.27%
0.26%
大文字化:
|
ボリューム (24 時間):